MedTrace Logo

Autologous Blood Products in Ridge Preservation

NCT07530471 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-15

No results posted yet for this study

Summary

This randomized controlled clinical trial aims to evaluate the clinical, radiographic, and ultrasonographic outcomes of alveolar ridge preservation using autologous blood products following tooth extraction.

After tooth extraction, dimensional changes occur in both hard and soft tissues, which may negatively affect future implant or prosthetic treatments. This study investigates whether the application of Titanium Platelet-Rich Fibrin (T-PRF), combined with injectable Platelet-Rich Fibrin (i-PRF), can improve healing and reduce tissue changes.

In this study, tooth extraction will be performed under local anesthesia using minimally invasive techniques. Autologous blood will be collected from the patient and processed by centrifugation to obtain T-PRF and i-PRF. The prepared materials will be applied to the extraction socket and stabilized with sutures. Healing will be monitored through clinical examinations, radiographic imaging, and ultrasonographic evaluations over a 6-month follow-up period.

Possible risks include pain, bleeding, infection, and temporary discomfort, all of which are manageable with standard clinical care.

The study is expected to contribute to the development of biologically based, minimally invasive treatment approaches that enhance tissue healing and support future dental treatments.

Conditions

  • Ridge Preservation

Interventions

PROCEDURE

Autologous Titanium Platelet-Rich Fibrin with Injectable PRF Application

Following atraumatic tooth extraction under local anesthesia, autologous blood will be collected from the patient. Titanium platelet-rich fibrin (T-PRF) will be prepared by centrifugation of blood in titanium tubes, and injectable platelet-rich fibrin (i-PRF) will be obtained using a low-speed centrifugation protocol. The prepared i-PRF will be injected into the T-PRF membrane to create a combined autologous fibrin construct. This material will then be placed into the extraction socket to support clot stability and tissue regeneration, and the site will be sutured for stabilization. This approach combines the dense fibrin structure of T-PRF with the biological activity of i-PRF, aiming to enhance angiogenesis, soft and hard tissue healing, and preservation of alveolar ridge dimensions.

Sponsors & Collaborators

  • Çanakkale Onsekiz Mart University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-01
Primary Completion
2026-11-01
Completion
2027-01-01

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07530471 on ClinicalTrials.gov